BACKGROUND: Gemcitabine- and 5-fluorouracil (5-FU)- based chemotherapy is a commonly used adjuvant or palliative treatment for patients with pancreatic cancer. However, a standard chemotherapy regimen has yet to be developed for patients refractory to gemcitabine and 5-FU treatment. We attempted to evaluate the efficacy and safety of a combination of irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer. PATIENTS AND METHODS: Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study. IROX chemotherapy was administered as follows: Irinotecan, 150 mg/m(2) on day 1; and oxaliplatin, 85 mg/m(2) on day 1 over 90 min every 2 weeks. RESULT: From Mar. 2006 to Dec. 2008, a total of 14 patients were administered 50 cycles of chemotherapy. The male-to-female ratio of the patient group was 11:3. These patients ranged in age from 48 to 73 years (median 65.5 years old). 3 patients (21.4%) evidenced partial responses. four patients (28.6%) exhibited stable disease. The median time to progression and overall survival time were 1.4 (95% CI: 1.2-1.6) months and 4.1 (95% CI: 2.0-6.2) months, respectively. Major hematologic toxicities included grade 1-2 anemia (88%), neutropenia (36%), thrombocytopenia (30%), and grade 3-4 neutropenia (10%). The most frequently detected non-hematological toxicities were grade 3 diarrheas (14%). CONCLUSION: The IROX regimen appears to constitute a feasible and tolerable salvage therapy in patients with advanced pancreatic cancer who have been previously treated with gemcitabine- and 5-FU-based chemotherapy.
BACKGROUND:Gemcitabine- and 5-fluorouracil (5-FU)- based chemotherapy is a commonly used adjuvant or palliative treatment for patients with pancreatic cancer. However, a standard chemotherapy regimen has yet to be developed for patients refractory to gemcitabine and 5-FU treatment. We attempted to evaluate the efficacy and safety of a combination of irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer. PATIENTS AND METHODS: Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study. IROX chemotherapy was administered as follows: Irinotecan, 150 mg/m(2) on day 1; and oxaliplatin, 85 mg/m(2) on day 1 over 90 min every 2 weeks. RESULT: From Mar. 2006 to Dec. 2008, a total of 14 patients were administered 50 cycles of chemotherapy. The male-to-female ratio of the patient group was 11:3. These patients ranged in age from 48 to 73 years (median 65.5 years old). 3 patients (21.4%) evidenced partial responses. four patients (28.6%) exhibited stable disease. The median time to progression and overall survival time were 1.4 (95% CI: 1.2-1.6) months and 4.1 (95% CI: 2.0-6.2) months, respectively. Major hematologic toxicities included grade 1-2 anemia (88%), neutropenia (36%), thrombocytopenia (30%), and grade 3-4 neutropenia (10%). The most frequently detected non-hematological toxicities were grade 3 diarrheas (14%). CONCLUSION: The IROX regimen appears to constitute a feasible and tolerable salvage therapy in patients with advanced pancreatic cancer who have been previously treated with gemcitabine- and 5-FU-based chemotherapy.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Amanda C Ashley; Daniel J Sargent; Steven R Alberts; Axel Grothey; Megan E Campbell; Roscoe F Morton; Charles S Fuchs; Ramesh K Ramanathan; Stephen K Williamson; Brian P Findlay; Henry C Pitot; Richard M Goldberg Journal: Cancer Date: 2007-08-01 Impact factor: 6.860
Authors: Seong Yoon Yi; Young Suk Park; Hyo Song Kim; Hyun Jung Jun; Kyoung Ha Kim; Myung Hee Chang; Min Jae Park; Ji Eun Uhm; Jeeyun Lee; Se Hoon Park; Joon Oh Park; Jong Kyun Lee; Kyu Taek Lee; Ho Yeong Lim; Won Ki Kang Journal: Cancer Chemother Pharmacol Date: 2008-10-07 Impact factor: 3.333
Authors: M Reni; L Pasetto; G Aprile; S Cordio; E Bonetto; S Dell'Oro; P Passoni; L Piemonti; C Fugazza; G Luppi; C Milandri; R Nicoletti; A Zerbi; G Balzano; V Di Carlo; A A Brandes Journal: Br J Cancer Date: 2006-03-27 Impact factor: 7.640
Authors: Hassan K Dakik; Daniel J Moskovic; Peter J Carlson; Eric P Tamm; Wei Qiao; Robert A Wolff; James L Abbruzzese; David R Fogelman Journal: Cancer Chemother Pharmacol Date: 2011-08-18 Impact factor: 3.333
Authors: M Bupathi; D H Ahn; C Wu; K K Ciombor; J A Stephens; J Reardon; D A Goldstein; T Bekaii-Saab Journal: Med Oncol Date: 2016-03-19 Impact factor: 3.064
Authors: A H Ko; M A Tempero; Y-S Shan; W-C Su; Y-L Lin; E Dito; A Ong; Y-W Wang; C G Yeh; L-T Chen Journal: Br J Cancer Date: 2013-07-23 Impact factor: 7.640